Evidence map›Paper›PMID 33795259›Full record

ArticleClinical cancer research : an official journal of the American Association for Cancer Research2021

Liquid Biopsy: It's the Bloody Truth!

Nathan M Hawkey, Andrew J Armstrong

Open access · bronzeAbstract readComment
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical cancer research : an official journal of the American Association for Cancer Research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.1field-weighted citation impact, top 51% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 citations in OpenAlex.

  1. Review
  2. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Nathan M HawkeyDivision of Hematology and Medical Oncology, Duke University, Durham, North Carolina.ORCID 0000-0003-2538-2423
Andrew J ArmstrongDuke Cancer Institute Center for Prostate and Urologic Cancers, Division of Medical Oncology and Urology, Duke Cancer Institute, Durham, North Carolina. andrew.armstrong@duke.edu.ORCID 0000-0001-7012-1754
Duke Medical Center · US

Funding

Clinical genomic predictive model of first line androgen receptor inhibitor therapy outcomes in men with mCRPCR01CA256157 · NCI · DUKE UNIVERSITY · PI ARMSTRONG, ANDREW J, DEHM, SCOTT M. · 2020 to 2025
$3.2M
Targeting convergent oncogenic signaling during AR inhibition to overcome metastasis and immune evasion in prostate cancerR01CA233585 · NCI · DUKE UNIVERSITY · PI ARMSTRONG, ANDREW J · 2019 to 2023
$2.2M
NCI NIH HHS R01 CA233585NCI NIH HHS R01 CA256157
6 · The paper itself

Abstract

Liquid biopsy is a promising clinical tool that can provide critical information for prognostication and which may inform treatment decisions in men with metastatic castration-resistant prostate cancer. Here we discuss the Foundation Medicine plasma cell-free circulating tumor DNA assay, its pros and cons, and potential clinical utility.

Indexed as

Circulating Tumor DNAProstatic NeoplasmsHumansLiquid BiopsyMaleCirculating Tumor DNA

Identifiers

PMID33795259
PMCPMC8172457
OpenAlexW3150298929

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.